You just read:

Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019

News provided by

Eisai Inc.

May 16, 2019, 12:45 ET